Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab.

Ridker PM, Rose LM, Kastelein JJP, Santos RD, Wei C, Revkin J, Yunis C, Tardif JC, Shear CL; Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Investigators.

J Clin Lipidol. 2018 Jul - Aug;12(4):958-965. doi: 10.1016/j.jacl.2018.03.088. Epub 2018 Apr 3.

PMID:
29685591
2.

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients.

Ridker PM, Revkin J, Amarenco P, Brunell R, Curto M, Civeira F, Flather M, Glynn RJ, Gregoire J, Jukema JW, Karpov Y, Kastelein JJP, Koenig W, Lorenzatti A, Manga P, Masiukiewicz U, Miller M, Mosterd A, Murin J, Nicolau JC, Nissen S, Ponikowski P, Santos RD, Schwartz PF, Soran H, White H, Wright RS, Vrablik M, Yunis C, Shear CL, Tardif JC; SPIRE Cardiovascular Outcome Investigators.

N Engl J Med. 2017 Apr 20;376(16):1527-1539. doi: 10.1056/NEJMoa1701488. Epub 2017 Mar 17.

3.

Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab.

Ridker PM, Tardif JC, Amarenco P, Duggan W, Glynn RJ, Jukema JW, Kastelein JJP, Kim AM, Koenig W, Nissen S, Revkin J, Rose LM, Santos RD, Schwartz PF, Shear CL, Yunis C; SPIRE Investigators.

N Engl J Med. 2017 Apr 20;376(16):1517-1526. doi: 10.1056/NEJMoa1614062. Epub 2017 Mar 17.

4.

Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial.

Tricoci P, D'Andrea DM, Gurbel PA, Yao Z, Cuchel M, Winston B, Schott R, Weiss R, Blazing MA, Cannon L, Bailey A, Angiolillo DJ, Gille A, Shear CL, Wright SD, Alexander JH.

J Am Heart Assoc. 2015 Aug 25;4(8):e002171. doi: 10.1161/JAHA.115.002171.

5.

CSL112 enhances biomarkers of reverse cholesterol transport after single and multiple infusions in healthy subjects.

Gille A, Easton R, D'Andrea D, Wright SD, Shear CL.

Arterioscler Thromb Vasc Biol. 2014 Sep;34(9):2106-14. doi: 10.1161/ATVBAHA.114.303720. Epub 2014 Jun 26.

PMID:
24969776
6.

Relationship between atorvastatin dose and the harm caused by torcetrapib.

Barter PJ, Rye KA, Beltangady MS, Ports WC, Duggan WT, Boekholdt SM, DeMicco DA, Kastelein JJ, Shear CL.

J Lipid Res. 2012 Nov;53(11):2436-42. doi: 10.1194/jlr.P026328. Epub 2012 Sep 2.

7.

Ultrasound protocols to measure carotid intima-media thickness in trials; comparison of reproducibility, rate of progression, and effect of intervention in subjects with familial hypercholesterolemia and subjects with mixed dyslipidemia.

Dogan S, Duivenvoorden R, Grobbee DE, Kastelein JJ, Shear CL, Evans GW, Visseren FL, Bots ML; Radiance 1 and Radiance 2 Study Groups.

Ann Med. 2010 Sep;42(6):447-64. doi: 10.3109/07853890.2010.499132.

PMID:
20645885
8.

Completeness of carotid intima media thickness measurements depends on body composition: the RADIANCE 1 and 2 trials.

Dogan S, Duivenvoorden R, Grobbee DE, Kastelein JJ, Shear CL, Evans GW, Visseren FL, Bots ML; Radiance 1 and 2 Study Groups.

J Atheroscler Thromb. 2010 May;17(5):526-35. Epub 2010 Mar 13.

9.

The failure of torcetrapib: is there a case for independent preclinical and clinical testing?--correspondence.

Shear CL.

Expert Opin Pharmacother. 2008 Oct;9(14):2561-2; author reply 2563-4. doi: 10.1517/14656566.9.14.2561 . No abstract available.

PMID:
18778194
10.

Effects of torcetrapib in patients at high risk for coronary events.

Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B; ILLUMINATE Investigators.

N Engl J Med. 2007 Nov 22;357(21):2109-22. Epub 2007 Nov 5.

11.

Inhibition of CETP by torcetrapib attenuates the atherogenicity of postprandial TG-rich lipoproteins in type IIB hyperlipidemia.

Guerin M, Le Goff W, Duchene E, Julia Z, Nguyen T, Thuren T, Shear CL, Chapman MJ.

Arterioscler Thromb Vasc Biol. 2008 Jan;28(1):148-54. Epub 2007 Oct 19.

PMID:
17951324
12.

Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial.

Bots ML, Visseren FL, Evans GW, Riley WA, Revkin JH, Tegeler CH, Shear CL, Duggan WT, Vicari RM, Grobbee DE, Kastelein JJ; RADIANCE 2 Investigators.

Lancet. 2007 Jul 14;370(9582):153-160. doi: 10.1016/S0140-6736(07)61088-5.

PMID:
17630038
13.
14.

Designs of RADIANCE 1 and 2: carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis.

Kastelein JJ, van Leuven SI, Evans GW, Riley WA, Revkin JH, Shear CL, Bots ML; RADIANCE 1 and 2 Study Investigators.

Curr Med Res Opin. 2007 Apr;23(4):885-94.

PMID:
17407645
15.

Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.

Kastelein JJ, van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, Revkin JH, Grobbee DE, Riley WA, Shear CL, Duggan WT, Bots ML; RADIANCE 1 Investigators.

N Engl J Med. 2007 Apr 19;356(16):1620-30. Epub 2007 Mar 26.

16.

Effect of torcetrapib on the progression of coronary atherosclerosis.

Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Tuzcu EM; ILLUSTRATE Investigators.

N Engl J Med. 2007 Mar 29;356(13):1304-16. Epub 2007 Mar 26. Erratum in: N Engl J Med. 2007 Aug 23;357(8):835. Lasala, Gregory P [corrected to Lasala, Gabriel P].

17.

Biomarkers in the prevention and treatment of atherosclerosis: need, validation, and future.

Revkin JH, Shear CL, Pouleur HG, Ryder SW, Orloff DG.

Pharmacol Rev. 2007 Mar;59(1):40-53. Review.

PMID:
17329547
18.

Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL.

Yvan-Charvet L, Matsuura F, Wang N, Bamberger MJ, Nguyen T, Rinninger F, Jiang XC, Shear CL, Tall AR.

Arterioscler Thromb Vasc Biol. 2007 May;27(5):1132-8. Epub 2007 Feb 22.

PMID:
17322101
21.

Torcetrapib and atorvastatin.

Shear CL.

N Engl J Med. 2005 Oct 6;353(14):1527-9; author reply 1527-9. No abstract available.

PMID:
16207861
22.

Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate.

Fontaine KR, Heo M, Harrigan EP, Shear CL, Lakshminarayanan M, Casey DE, Allison DB.

Psychiatry Res. 2001 Apr 15;101(3):277-88.

PMID:
11311931
23.

Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up.

Bradford RH, Shear CL, Chremos AN, Dujovne CA, Franklin FA, Grillo RB, Higgins J, Langendorfer A, Nash DT, Pool JL, et al.

Am J Cardiol. 1994 Oct 1;74(7):667-73.

PMID:
7942524
24.

Efficacy and tolerability of lovastatin in 3390 women with moderate hypercholesterolemia.

Bradford RH, Downton M, Chremos AN, Langendörfer A, Stinnett S, Nash DT, Mantell G, Shear CL.

Ann Intern Med. 1993 Jun 1;118(11):850-5.

PMID:
8480959
25.

The case for unstable angina pectoris as a primary end point in primary prevention studies.

Whitney EJ, Shear CL, Mantell G, Lydick E, Wolf R.

Am J Cardiol. 1992 Sep 15;70(7):738-43.

PMID:
1519523
26.

Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. Effect of patient characteristics on lovastatin-induced changes in plasma concentrations of lipids and lipoproteins.

Shear CL, Franklin FA, Stinnett S, Hurley DP, Bradford RH, Chremos AN, Nash DT, Langendorfer A.

Circulation. 1992 Apr;85(4):1293-303.

PMID:
1555273
27.

Lovastatin and coadministered antihypertensive/cardiovascular agents.

Pool JL, Shear CL, Downton M, Schnaper H, Stinnett S, Dujovne C, Bradford RH, Chremos AN.

Hypertension. 1992 Mar;19(3):242-8.

PMID:
1347757
28.

Expanded clinical evaluation of lovastatin (EXCEL) study results: III. Efficacy in modifying lipoproteins and implications for managing patients with moderate hypercholesterolemia.

Bradford RH, Shear CL, Chremos AN, Franklin FA, Nash DT, Hurley DP, Dujovne CA, Pool JL, Schnaper H, Hesney M, et al.

Am J Med. 1991 Jul 31;91(1B):18S-24S.

PMID:
1867232
29.

Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin.

Dujovne CA, Chremos AN, Pool JL, Schnaper H, Bradford RH, Shear CL, Higgins J, Downton M, Franklin FA, Nash DT, et al.

Am J Med. 1991 Jul 31;91(1B):25S-30S.

PMID:
1831006
30.

Expanded clinical evaluation of lovastatin (EXCEL) study results. II. Assessment of the human lens after 48 weeks of treatment with lovastatin.

Laties AM, Shear CL, Lippa EA, Gould AL, Taylor HR, Hurley DP, Stephenson WP, Keates EU, Tupy-Visich MA, Chremos AN.

Am J Cardiol. 1991 Mar 1;67(6):447-53.

PMID:
1998274
31.

Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia.

Bradford RH, Shear CL, Chremos AN, Dujovne C, Downton M, Franklin FA, Gould AL, Hesney M, Higgins J, Hurley DP, et al.

Arch Intern Med. 1991 Jan;151(1):43-9.

PMID:
1985608
32.

Expanded clinical evaluation of lovastatin (EXCEL) study: design and patient characteristics of a double-blind, placebo-controlled study in patients with moderate hypercholesterolemia.

Bradford RH, Shear CL, Chremos AN, Dujovne C, Franklin FA, Hesney M, Higgins J, Langendörfer A, Pool JL, Schnaper H, et al.

Am J Cardiol. 1990 Sep 18;66(8):44B-55B.

PMID:
2206036
33.

The human lens after 48 weeks of treatment with lovastatin.

Laties AM, Keates EU, Taylor HR, Chremos AN, Shear CL, Lippa EA, Gould AL, Hurley DP.

N Engl J Med. 1990 Sep 6;323(10):683-4. No abstract available.

PMID:
2385275
34.

Clinical experience with lovastatin.

Tobert JA, Shear CL, Chremos AN, Mantell GE.

Am J Cardiol. 1990 Mar 20;65(12):23F-26F.

PMID:
2180268
35.

Combined low-dose medication and primary intervention over a 30-month period for sustained high blood pressure in childhood.

Berenson GS, Shear CL, Chiang YK, Webber LS, Voors AW.

Am J Med Sci. 1990 Feb;299(2):79-86.

PMID:
2301454
36.

Risk factors in early life as predictors of adult heart disease: the Bogalusa Heart Study.

Berenson GS, Srinivasan SR, Hunter SM, Nicklas TA, Freedman DS, Shear CL, Webber LS.

Am J Med Sci. 1989 Sep;298(3):141-51. Review.

PMID:
2679086
37.

Secular trends of obesity in early life: the Bogalusa Heart Study.

Shear CL, Freedman DS, Burke GL, Harsha DW, Webber LS, Berenson GS.

Am J Public Health. 1988 Jan;78(1):75-7.

38.

Cardiovascular risk factors from birth to 7 years of age: the Bogalusa Heart Study. Blood pressure.

Burke GL, Voors AW, Shear CL, Webber LS, Smoak CG, Cresanta JL, Berenson GS.

Pediatrics. 1987 Nov;80(5 Pt 2):784-8.

PMID:
3670989
39.

Relation of body fat distribution to hyperinsulinemia in children and adolescents: the Bogalusa Heart Study.

Freedman DS, Srinivasan SR, Burke GL, Shear CL, Smoak CG, Harsha DW, Webber LS, Berenson GS.

Am J Clin Nutr. 1987 Sep;46(3):403-10.

PMID:
3307372
40.

Correlates of high density lipoprotein cholesterol and apolipoprotein A-I levels in children. The Bogalusa Heart Study.

Freedman DS, Srinivasan SR, Shear CL, Webber LS, Chiang YK, Berenson GS.

Arteriosclerosis. 1987 Jul-Aug;7(4):354-60.

PMID:
3300617
41.

Persistence of juvenile-onset obesity over eight years: the Bogalusa Heart Study.

Freedman DS, Shear CL, Burke GL, Srinivasan SR, Webber LS, Harsha DW, Berenson GS.

Am J Public Health. 1987 May;77(5):588-92.

42.

Body fat patterning and blood pressure in children and young adults. The Bogalusa Heart Study.

Shear CL, Freedman DS, Burke GL, Harsha DW, Berenson GS.

Hypertension. 1987 Mar;9(3):236-44.

PMID:
3818021
43.

Sources of error in measurement of children's blood pressure in a large epidemiologic study: Bogalusa Heart Study.

Burke GL, Webber LS, Shear CL, Zinkgraf SA, Smoak CG, Berenson GS.

J Chronic Dis. 1987;40(1):83-9.

PMID:
3805236
44.
45.

The relation of apolipoproteins A-I and B in children to parental myocardial infarction.

Freedman DS, Srinivasan SR, Shear CL, Franklin FA, Webber LS, Berenson GS.

N Engl J Med. 1986 Sep 18;315(12):721-6.

PMID:
3092050
46.

Cigarette smoking initiation and longitudinal changes in serum lipids and lipoproteins in early adulthood: the Bogalusa Heart Study.

Freedman DS, Srinivasan SR, Shear CL, Hunter SM, Croft JB, Webber LS, Berenson GS.

Am J Epidemiol. 1986 Aug;124(2):207-19.

PMID:
3728437
47.

Determinants of no-show appointment behavior: the utility of multivariate analysis.

Gruzd DC, Shear CL, Rodney WM.

Fam Med. 1986 Jul-Aug;18(4):217-20.

PMID:
3556868
49.

Medical care at the 1982 US Festival.

Ounanian LL, Salinas C, Shear CL, Rodney WM.

Ann Emerg Med. 1986 May;15(5):520-7.

PMID:
3963530
50.

Cardiovascular risk factors and their modification in children.

Burke GL, Cresanta JL, Shear CL, Miner MH, Berenson GS.

Cardiol Clin. 1986 Feb;4(1):33-46. Review.

PMID:
3518933

Supplemental Content

Loading ...
Support Center